Welcome to our dedicated page for OKYO PHARMA SEC filings (Ticker: OKYO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission filings for OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on neuropathic corneal pain, dry eye disease, and ocular inflammatory conditions. As a foreign private issuer, OKYO submits Form 6-K reports under the Securities Exchange Act of 1934, which furnish key company announcements to investors.
Recent 6-K filings referenced in public disclosures include exhibits covering share acquisitions by Panetta Partners Limited, an entity in which OKYO’s Executive Chairman has a beneficial interest, with details on the number of ordinary shares acquired on NASDAQ and updated total holdings. Other 6-Ks furnish announcements about clinical development milestones, such as the registration pathway and planned 100-patient multi-center trial of urcosimod in neuropathic corneal pain, as well as notices of management presentations at industry meetings like the Ophthalmology Innovation Summit and BIO-Europe.
Through Stock Titan, users can access these filings as they are made available from EDGAR and review the attached exhibits that describe OKYO’s clinical progress, regulatory plans, and significant ownership changes. AI-powered summaries help explain the contents of each filing in plain language, highlighting why a particular 6-K may matter for understanding OKYO’s development of urcosimod and its broader ophthalmology strategy.
For investors analyzing OKYO, this filings page offers a structured way to follow its ongoing disclosure record, from clinical trial updates and registration pathway discussions to insider-related share purchases reported via Form 6-K. The combination of real-time access and AI-generated insights can support more efficient review of OKYO’s regulatory communications.
OKYO Pharma is highlighting its eye disease program through upcoming scientific meetings and recent clinical data. The CEO will present at Eyecelerator on May 1, 2026, and the Chief Scientific Officer will present Phase 2 data at the ARVO Annual Meeting in Denver in early May.
The company’s lead drug, urcosimod, is an investigational therapy for neuropathic corneal pain (NCP) and inflammatory eye diseases. It is the first therapy to receive an IND specifically for NCP and has Fast Track designation from the U.S. FDA. OKYO reports clinically meaningful pain reduction and quality-of-life improvement in an 18-patient randomized, placebo-controlled, double-masked Phase 2 NCP trial, and statistically significant results in an earlier 240-patient Phase 2 dry eye disease trial. OKYO plans to start a 150-patient Phase 2b/3 multiple-dose NCP study in the first half of the year.
OKYO Pharma is highlighting progress for its lead eye therapy, urcosimod, around the 2026 ASCRS meeting in Washington, DC. The company will convene a Scientific Advisory Board of leading ophthalmology experts to review Phase 2 clinical data and guide the next clinical program.
In parallel, principal investigator Dr. Pedram Hamrah will present Phase 2 proof-of-concept results on urcosimod in neuropathic corneal pain, covering efficacy and safety. Urcosimod holds an IND and FDA Fast Track designation for this indication, and OKYO plans a 150-patient Phase 2b/3 multiple-dose study in the first half of 2026.
OKYO Pharma filed a report highlighting an insider share purchase by Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest. Panetta Partners acquired 10,119 ordinary shares on Nasdaq at $1.59, bringing Cerrone’s total holding to 10,526,416 shares.
The filing also reiterates OKYO’s clinical focus on neuropathic corneal pain and inflammatory eye diseases. Its lead candidate, urcosimod, has shown pain reduction in Phase 2 studies, and the company plans to start a ~150‑subject Phase 2b/3 multiple‑dose NCP study in the first half of this year.
OKYO Pharma filed a report highlighting an insider share purchase by Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest. Panetta Partners acquired 10,119 ordinary shares on Nasdaq at $1.59, bringing Cerrone’s total holding to 10,526,416 shares.
The filing also reiterates OKYO’s clinical focus on neuropathic corneal pain and inflammatory eye diseases. Its lead candidate, urcosimod, has shown pain reduction in Phase 2 studies, and the company plans to start a ~150‑subject Phase 2b/3 multiple‑dose NCP study in the first half of this year.
OKYO Pharma filed a report highlighting an insider share purchase by Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest. Panetta Partners acquired 10,119 ordinary shares on Nasdaq at $1.59, bringing Cerrone’s total holding to 10,526,416 shares.
The filing also reiterates OKYO’s clinical focus on neuropathic corneal pain and inflammatory eye diseases. Its lead candidate, urcosimod, has shown pain reduction in Phase 2 studies, and the company plans to start a ~150‑subject Phase 2b/3 multiple‑dose NCP study in the first half of this year.
OKYO Pharma Limited filed a report noting that Non-Executive Director John Brancaccio acquired 5,000 ordinary shares on Nasdaq at $1.61 per share, increasing his holding to 31,201 shares. The company also highlights urcosimod, its lead drug candidate for neuropathic corneal pain and inflammatory eye diseases, which has shown anti-inflammatory and pain-reducing activity in preclinical models. OKYO recently reported positive pain-reduction data from a randomized, placebo-controlled, double-masked Phase 2a trial in 18 neuropathic corneal pain subjects and earlier significant pain reduction in a 240-subject Phase 2 dry eye disease trial. The company plans to start an approximately 150-subject Phase 2b/3 multiple-dose study of urcosimod in neuropathic corneal pain in the first half of the year.
OKYO Pharma Limited filed a report noting that Non-Executive Director John Brancaccio acquired 5,000 ordinary shares on Nasdaq at $1.61 per share, increasing his holding to 31,201 shares. The company also highlights urcosimod, its lead drug candidate for neuropathic corneal pain and inflammatory eye diseases, which has shown anti-inflammatory and pain-reducing activity in preclinical models. OKYO recently reported positive pain-reduction data from a randomized, placebo-controlled, double-masked Phase 2a trial in 18 neuropathic corneal pain subjects and earlier significant pain reduction in a 240-subject Phase 2 dry eye disease trial. The company plans to start an approximately 150-subject Phase 2b/3 multiple-dose study of urcosimod in neuropathic corneal pain in the first half of the year.
OKYO Pharma Limited filed a report noting that Non-Executive Director John Brancaccio acquired 5,000 ordinary shares on Nasdaq at $1.61 per share, increasing his holding to 31,201 shares. The company also highlights urcosimod, its lead drug candidate for neuropathic corneal pain and inflammatory eye diseases, which has shown anti-inflammatory and pain-reducing activity in preclinical models. OKYO recently reported positive pain-reduction data from a randomized, placebo-controlled, double-masked Phase 2a trial in 18 neuropathic corneal pain subjects and earlier significant pain reduction in a 240-subject Phase 2 dry eye disease trial. The company plans to start an approximately 150-subject Phase 2b/3 multiple-dose study of urcosimod in neuropathic corneal pain in the first half of the year.
OKYO Pharma Limited reports that its Chief Development Officer and Director, Gary Jacob, has acquired 30,980 ordinary shares on Nasdaq at $1.59 per share, increasing his holding to 108,920 shares. The company highlights its lead candidate urcosimod, which has shown anti-inflammatory and pain‑reducing effects in preclinical models and positive pain‑reduction data in an 18‑subject Phase 2a neuropathic corneal pain trial and a prior 240‑subject dry eye disease trial. OKYO recently completed a successful Phase 2 trial in neuropathic corneal pain and plans a ~150‑subject Phase 2b/3 multiple‑dose study in the first half of this year.
OKYO Pharma Limited reports that its Chief Development Officer and Director, Gary Jacob, has acquired 30,980 ordinary shares on Nasdaq at $1.59 per share, increasing his holding to 108,920 shares. The company highlights its lead candidate urcosimod, which has shown anti-inflammatory and pain‑reducing effects in preclinical models and positive pain‑reduction data in an 18‑subject Phase 2a neuropathic corneal pain trial and a prior 240‑subject dry eye disease trial. OKYO recently completed a successful Phase 2 trial in neuropathic corneal pain and plans a ~150‑subject Phase 2b/3 multiple‑dose study in the first half of this year.
OKYO Pharma Limited reports that its Chief Development Officer and Director, Gary Jacob, has acquired 30,980 ordinary shares on Nasdaq at $1.59 per share, increasing his holding to 108,920 shares. The company highlights its lead candidate urcosimod, which has shown anti-inflammatory and pain‑reducing effects in preclinical models and positive pain‑reduction data in an 18‑subject Phase 2a neuropathic corneal pain trial and a prior 240‑subject dry eye disease trial. OKYO recently completed a successful Phase 2 trial in neuropathic corneal pain and plans a ~150‑subject Phase 2b/3 multiple‑dose study in the first half of this year.
OKYO Pharma Ltd Chief Development Officer Gary S. Jacob filed an initial ownership report showing he holds 108,920 shares of common stock directly. He also reports multiple option awards over common stock with exercise prices ranging from 1.46 to 2.75 per share and expirations between 2033 and 2035.
OKYO Pharma Ltd director and ten percent owner Gabriele M. Cerrone has filed an initial ownership report on Form 3. The filing shows that he directly holds 10,526,416 shares of common stock of OKYO Pharma Ltd following the reported position, establishing his status as a significant shareholder.
OKYO Pharma reported new exploratory Phase 2 data for its investigational eye therapy urcosimod 0.05% in neuropathic corneal pain (NCP). In a 12-week randomized, double-masked, placebo-controlled study, patients receiving urcosimod (n=6) showed greater improvements in several patient-reported quality-of-life measures versus placebo (n=6).
On a 0–10 scale, mean change in enjoying life/relationships was −4.5 for urcosimod compared with 0 for placebo, mood improved by −1.5 versus −0.5, and time spent thinking about eye pain fell by −3.0 versus −1.5. These outcomes build on previously reported Visual Analogue Scale pain reductions and suggest broader emotional and functional benefits.
The new data will be presented at the ARVO 2026 Annual Meeting and support OKYO’s plan for larger confirmatory development, including a multi-center Phase 2b/3 trial in NCP, a debilitating condition with no FDA-approved therapies.
OKYO Pharma Limited reports that the underwriter has partially exercised its option to buy extra shares from the company in a recent equity offering. Piper Sandler & Co. purchased an additional 1,109,060 ordinary shares on March 12, 2026, lifting total gross proceeds from the underwritten public offering to approximately $22 million before fees and expenses. This follows the initial sale of 10,815,000 ordinary shares at $1.85 per share, all issued by the company under an effective Form F-3 shelf registration.
OKYO Pharma Limited filed a Form 6-K highlighting that its abstract on urcosimod for neuropathic corneal pain (NCP) was accepted for presentation at the ARVO 2026 Annual Meeting in Denver. Chief Scientific Officer Raj Patil, Ph.D., will present first-in-human data showing clinically meaningful pain reduction on the Visual Analogue Scale and improved quality-of-life metrics in NCP patients.
The Phase 2a proof-of-concept trial of urcosimod, a novel non-opioid, preservative-free eye drop with dual pain-relieving and anti-inflammatory activity, also suggested potential restoration of corneal nerve structure. Urcosimod holds FDA Fast Track designation and the first IND clearance specifically for NCP, and OKYO plans to initiate an approximately 150-patient multicenter Phase 2b/3 study in the first half of this year.